Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korro Bio, Inc.KRRO · Entity 6388 | Director | June 11, 2024 | June 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korro Bio, Inc.
Report date June 11, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.19 · Expires 2034-06-10 | Direct | 5,190 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 5,190 · Balance 5,190 F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2021 Filed Feb 5, 2021 12:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,518 | $50.00 | $275,900.00 |
DisclosureSEC source: 0001127602-21-004085 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 12:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 5,518 | $47.50 | $262,105.00 |
DisclosureSEC source: 0001127602-21-004085 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,604 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 12:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 11,036 | $0.61 | $6,731.96 |
DisclosureSEC source: 0001127602-21-004085 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 5,518 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-004039 · form4.xml · derivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,031 Underlying: Common Stock · 5,518 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 9 | $47.36 | $426.24 |
DisclosureSEC source: 0001127602-21-004039 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,709 | $46.84 | $80,051.44 |
DisclosureSEC source: 0001127602-21-004039 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,095 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $46.25 to $47.2. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 3,800 | $45.76 | $173,882.30 |
DisclosureSEC source: 0001127602-21-004039 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,804 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $45.175 to $46.14. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:44 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 5,518 | $0.61 | $3,365.98 |
DisclosureSEC source: 0001127602-21-004039 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 33,102 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · derivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,549 Underlying: Common Stock · 33,102 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,702 | $44.58 | $120,459.21 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $44.4400 to $44.7250. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,900 | $43.71 | $389,056.38 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $43.3100 to $44.2400. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 18,600 | $42.85 | $797,099.28 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,688 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $42.2950 to $43.2800. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,900 | $41.29 | $119,755.21 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $40.87 to $41.695. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 33,102 | $0.61 | $20,192.22 |
DisclosureSEC source: 0001127602-21-003799 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 22:27 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 9,196 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-002862 · form4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,651 Underlying: Common Stock · 9,196 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 22:27 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 9,196 | $42.50 | $390,830.00 |
DisclosureSEC source: 0001127602-21-002862 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 22:27 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 9,196 | $0.61 | $5,609.56 |
DisclosureSEC source: 0001127602-21-002862 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:50 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $35.85 | $0.00 |
DisclosureSEC source: 0001127602-21-002012 · form4.xml · derivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-01-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 27,586 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · derivative · entry 7 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,847 Underlying: Common Stock · 27,586 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 9,496 | $40.00 | $379,809.61 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F6 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $39.85 to $40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,319 | $39.37 | $91,299.03 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,582 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $38.83 to $39.82. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,164 | $38.26 | $159,314.64 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,901 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $37.73 to $38.72. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 10,707 | $37.45 | $400,977.15 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,065 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $36.66 to $37.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 900 | $36.13 | $32,517.00 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,772 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $35.60 to $36.55. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 12:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 27,586 | $0.61 | $16,827.46 |
DisclosureSEC source: 0001127602-21-001230 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 14,477 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · derivative · entry 7 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,433 Underlying: Common Stock · 14,477 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 3,913 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · derivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,913 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and became fully vested and exercisable on January 1, 2021. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 100 | $35.46 | $3,546.23 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $35.45 to $35.59. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 11,763 | $33.81 | $397,731.73 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,186 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $33.545 to $34.5. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 22,241 | $32.89 | $731,462.01 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,949 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $32.545 to $33.535. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 14,477 | $0.61 | $8,830.97 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:53 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 3,913 | $0.61 | $2,386.93 |
DisclosureSEC source: 0001127602-21-001043 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 1,120 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-032105 · form4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,910 Underlying: Common Stock · 1,120 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,120 | $42.64 | $47,755.23 |
DisclosureSEC source: 0001127602-20-032105 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $42.5 to $42.76. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:51 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 1,120 | $0.61 | $683.20 |
DisclosureSEC source: 0001127602-20-032105 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 13,514 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · derivative · entry 12 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,030 Underlying: Common Stock · 13,514 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 13,514 | $40.00 | $540,560.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 8 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 13,514 | $0.61 | $8,243.54 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 7 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 7,103 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · derivative · entry 11 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,544 Underlying: Common Stock · 7,103 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 6,411 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · derivative · entry 10 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,913 Underlying: Common Stock · 6,411 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,500 | $38.83 | $174,735.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 6 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $38.505 to $39.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 9,014 | $38.18 | $344,154.52 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 5 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $37.5 to $38.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 7,103 | $0.61 | $4,332.83 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 4 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 6,411 | $0.61 | $3,910.71 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 13,514 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · derivative · entry 9 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,324 Underlying: Common Stock · 13,514 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 13,514 | $35.12 | $474,611.68 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $35.08 to $35.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 01:01 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 13,514 | $0.61 | $8,243.54 |
DisclosureSEC source: 0001127602-20-031626 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 22:25 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 13,514 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001127602-20-031115 · form4.xml · derivative · entry 3 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,838 Underlying: Common Stock · 13,514 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 22:25 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 13,514 | $32.93 | $444,983.59 |
DisclosureSEC source: 0001127602-20-031115 · form4.xml · nonDerivative · entry 2 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $32.5 to $33.285. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 22:25 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 13,514 | $0.61 | $8,243.54 |
DisclosureSEC source: 0001127602-20-031115 · form4.xml · nonDerivative · entry 1 Lucchino David L. · CIK 0001785288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.